Actively Recruiting
Study of Trilaciclib and Lurbinectidin
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-03-30
30
Participants Needed
2
Research Sites
323 weeks
Total Duration
On this page
Sponsors
U
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor
G
G1 Therapeutics, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is no consensus regarding subsequent therapy. Lurbinectedin is FDA approved and is increasingly preferred in clinical practice. Toxicity was significant, but appeared favorable compared to historic results with topotecan, leading to the adoption of this therapy for second-line SCLC. The toxicity profile was dominated by myelosuppression. This study investigates the effect of Trilaciclib on myelosuppression rate in subjects with platinum refractory extensive stage (ES)- SCLC receiving Lurbinectedin as well as the clinical synergy of Trilaciclib and Lurbinectedin combination.
CONDITIONS
Official Title
Study of Trilaciclib and Lurbinectidin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
- Age �3e= 18 years at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- Measurable disease according to RECIST v1.1 within 28 days prior to start of treatment.
- Previous treatment with a platinum agent, PD1 or PDL1 agent.
You will not qualify if you...
- Active infection requiring systemic therapy.
- Pregnant or breastfeeding (breast milk cannot be stored for future use while the mother is being treated on study).
- Treatment with any investigational drug within 4 weeks prior to start of treatment.
- Known allergy or sensitivity to either study drug or its excipients.
- Receiving prohibited medications or treatments as listed in the protocol.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Withdrawn
2
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
Research Team
S
Shamina Williams
CONTACT
L
Lauren Higgins
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here